Tag Archives: Tuberculosis

Opportunities and Challenges to Develop Effective Strategies for Private Sector Engagement to end Tuberculosis in India

Resource Type: Publication Authors:  Amaltas Consulting Published: August 2017 Resource Description: This study undertakes a Political Economy Analysis (PEA) of the participation of private health care providers in tuberculosis care in four states (Bihar, Gujarat, Maharashtra, and West Bengal) in India to improve understanding of how their involvement in the national program could be enhanced. In […]

TB day lead

On World TB Day, Focusing on Health Financing to End Tuberculosis

In the effort to end Tuberculosis—one of the leading causes of death from infectious disease worldwide—overall health system improvements are crucial. Despite substantial funding for TB prevention and treatment by donors and governments over the last decade, the worldwide incidence of TB remains high. In 2015 TB killed more than 1.8 million people, according to the World […]

HFG Rapid Assessment of TB Payment and PFM Systems in the Philippines: Lessons Learned and Policy Implications

In the Philippines, there are roughly 290,000 new TB cases per year (WHO, 2016). Meanwhile, donor funding for TB has declined, health care costs are rising, and out-of-pocket spending accounts for roughly two-thirds of national TB expenditures. The Philippines needs to identify mechanisms to improve the efficiency of TB spending

HFG Rapid Assessment of TB Payment and PFM Systems in Cambodia: Lessons Learned and Policy Implications

Despite substantial funding for tuberculosis (TB) prevention and treatment over the last 10 years, both by donors and governments, the worldwide incidence of TB remains troubling. Across lower- and middle-income countries, access to TB services is limited, and the quality of TB services is often substandard.

payment_system_tb_hospitals

Kyrgyzstan Modernizes TB Hospital Financing

The Kyrgyz Republic, a former Soviet Union country bordering China, has one of the highest rates of the difficult-to-treat multidrug resistant (MDR) tuberculosis in the world—with 26 percent of new TB cases estimated to be MDR, compared to 3 percent of new TB cases worldwide. According to the World Health Organization (WHO), only 55 percent […]

Back to Top